Abstract
Introduction

In the last decades, conventional chemotherapy has become one of the major medical intervention strategies for certain malignancies. The introduction of targeted molecular therapies directed against cancer-specific molecules and signalling pathways has further increased therapy responses and survival rates of patients with solid and haematological malignancies. However, one prominent exception is pancreatic ductal adenocarcinoma (PDAC), where 5-year survival rates are below 1%
and effective conservative therapies are missing [1, 2] . 'Biologicals', e.g. the epidermal growth factor receptor inhibitor erlotinib, are only effective in subsets of PDAC patients [3] . [4] . This review recapitulates the current knowledge on molecular functions and actions of HDACs and HDACI in PDACs.
Therefore, there is the need to develop new concepts for the treatment of PDAC. Targeting histone deacetylases (HDACs) could be a promising approach. However, functions of HDAC isoenzymes in PDAC and rationally based combination therapies still have to be identified for successful applications of HDAC inhibitors (HDACI) in the clinic. Since a recent phase II study revealed no advantage of combining gemcitabine with the HDACI CI-994 in patients with advanced PDAC, alternative HDACI-based combinations should be considered
The HDAC family
According to phylogenetic analyses and sequence homology, deacetylases can be grouped in class I to IV enzymes (Fig. 1) [9] .
Considering phylogenetic analyses, which demonstrate that classical HDACs precede the evolution of histone proteins, it is not surprising that a continuously growing number of nonhistone substrates of HDACs and HATs are described [9, 10] . Many of these proteins are transcription factors, such as p53, NF-B and STATs, and therefore changes in the transcriptome upon HDACI treatment can be due to a direct modulation of the 'histone code' or the consequence of an indirect modulation of transcription factor activities [9] [10] [11] (Fig. 2) . HDACs function in multiprotein complexes containing co-repressors and co-activators. Since HDACs are involved in the control of proliferation, apoptosis, differentiation, migration and angiogenesis in cancer [12] (Fig. 2) , they represent attractive therapeutic targets. In 2006, the HDACI suberoylanilide hydroxamic acid (SAHA) was approved by the FDA for the treatment of cutaneous T-cell lymphoma [13, 14] .
HDAC inhibitors
Several natural and synthetic compounds are currently known to inhibit HDACs [15, 16] . Since HDACI do not inhibit all HDAC isoforms to the same extent, these agents can be grouped into panand class I-specific inhibitors [16] . Hydroxamic 
HDAC expression in PDAC
Although overexpression of class I HDACs is a common feature of solid tumours, systematic analysis of HDAC expression in larger PDAC cohorts have not been reported yet [11, 18] 
Concluding remarks
Well characterized molecular pathways that HDACs engage in PDACs are summarized in Fig. 3 
